Literature DB >> 3153059

Vitamin D metabolite profiles in moderate renal insufficiency of childhood.

A Taylor1, M E Norman.   

Abstract

In a prior study, we reported vitamin D metabolite profiles in the plasma of healthy children. In view of these findings, we investigated these same profiles in children with moderate renal insufficiency. Specimens were obtained in both summer and winter in untreated patients, and before and after treatment for up to 1 year, with either 25(OH)D3 or 1,25(OH)2D3. Mean pretreatment 1,25(OH)2D levels were normal. Levels of 25(OH)D3 were also normal and continued to vary with season. Mean pretreatment 24,25(OH)2D3 levels were significantly lower in patients and, interestingly, did not show the normal seasonal variation. Treatment with 25(OH)D3 resulted in consistent and sustained rises in 25(OH)D3 and 24,25(OH)2D3 levels, but no increase in 1,25(OH)2D levels. After 1,25(OH)2D3 treatment, 25(OH)D3 levels were unchanged but still showed seasonal variation in some patients, suggesting a lack of feedback control by 1,25(OH)2D3. Levels of 24,25(OH)2D3 were not significantly different from baseline values. Levels of 1,25(OH)2D increased initially then dropped to pretreatment levels or lower. Normal 1,25(OH)2D levels and reduced 24,25(OH)2D3 levels with the loss of seasonal variation suggests in our patients that the kidney was able to maintain 1,25(OH)2D levels at the expense of 24,25(OH)2D3 levels, presumably to preserve calcium homeostasis.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3153059     DOI: 10.1007/bf00853441

Source DB:  PubMed          Journal:  Pediatr Nephrol        ISSN: 0931-041X            Impact factor:   3.714


  42 in total

1.  Mineral metabolism in chronic renal failure with special reference to serum concentrations of 1.25(OH)2D and 24.25(OH)2D.

Authors:  C Christiansen; M S Christensen; F Melsen; P Rødbro; H F DeLuca
Journal:  Clin Nephrol       Date:  1981-01       Impact factor: 0.975

2.  25-hydroxyvitamin D3 metabolism by isolated perfused rat kidney.

Authors:  A M Rosenthal; G Jones; S W Kooh; D Fraser
Journal:  Am J Physiol       Date:  1980-07

3.  25-hydroxyvitamin D3 (calcifediol) therapy of juvenile renal osteodystrophy: beneficial effect on linear growth velocity.

Authors:  C B Langman; A T Mazur; R Baron; M E Norman
Journal:  J Pediatr       Date:  1982-05       Impact factor: 4.406

4.  Circulating vitamin D metabolite concentrations in childhood renal diseases.

Authors:  R W Chesney; A J Hamstra; R B Mazess; P Rose; H F DeLuca
Journal:  Kidney Int       Date:  1982-01       Impact factor: 10.612

5.  The 24-hydroxylation of 1,25-dihydroxyvitamin D3.

Authors:  Y Tanaka; L Castillo; H F DeLuca
Journal:  J Biol Chem       Date:  1977-02-25       Impact factor: 5.157

6.  Stimulation of 24,25-dihydroxyvitamin D3 production by 1,25-dihydroxyvitamin D3.

Authors:  Y Tanaka; H F DeLuca
Journal:  Science       Date:  1974-03       Impact factor: 47.728

7.  Effects of 25-OHD3 on renal function in pediatric patients with chronic renal failure.

Authors:  A T Mazur; M E Norman
Journal:  Miner Electrolyte Metab       Date:  1984

8.  Plasma vitamin D metabolite concentrations in chronic renal failure: effect of oral administration of 25-hydroxyvitamin D3.

Authors:  B P Halloran; P Schaefer; M Lifschitz; M Levens; R S Goldsmith
Journal:  J Clin Endocrinol Metab       Date:  1984-12       Impact factor: 5.958

9.  Interrelationship of serum 25-hydroxyvitamin D3 and 1,25-dihydroxyvitamin D in juvenile renal osteodystrophy after therapy with 25-hydroxyvitamin D3.

Authors:  A Taylor; M E Norman
Journal:  Metab Bone Dis Relat Res       Date:  1982

10.  Reduced plasma concentration of 1,25-dihydroxyvitamin D in children with moderate renal insufficiency.

Authors:  A A Portale; B E Booth; H C Tsai; R C Morris
Journal:  Kidney Int       Date:  1982-04       Impact factor: 10.612

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.